A study to assess effect of romosozumab vs. alendronate on serious cardiovascular (CV) events
Latest Information Update: 11 Sep 2020
At a glance
- Drugs Romosozumab (Primary) ; Alendronic acid
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- 11 Sep 2020 New trial record
- 22 Aug 2020 Results presented at the 2020 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases